Key result
Aspirin use following the arterial switch operation was associated with lower in-hospital mortality compared to no aspirin.
Why the study?
Aspirin may protect against coronary thromboembolism after the arterial switch operation, but it is used inconsistently and its benefits remain unknown.
Does aspirin use following the arterial switch operation reduce in-hospital mortality and adverse events in pediatric patients?
Cohort (n=6,350)
Yes
Does aspirin use following the arterial switch operation reduce in-hospital mortality and adverse events in pediatric patients?
Aspirin use following the arterial switch operation is increasing and is associated with reduced in-hospital mortality without increasing bleeding risk, though prospective studies are needed.
Answers are grounded in this paper and cite their sources.
May support aspirin after arterial switch without raising bleeding; leaves open need for randomized confirmation before practice change.
Background Aspirin has the potential of offering coronary arterial protection from thromboembolism for patients following the arterial switch operation (ASO) but is used inconsistently and the benefits are unknown. We sought to discern trends and outcomes associated with the use of aspirin following the ASO. Methods Patients undergoing the ASO were identified from the Pediatric Health Information System and divided into two groups: those who received aspirin post-ASO versus the nonaspirin group to evaluate trends, variations, and outcomes. Results A total of 6,350 ASO cases were identified (44 centers) of which 1,751 (27.6%) were in the aspirin group. Aspirin was started after a median postoperative duration of four days (interquartile range: 1-7). The aspirin group was more likely to have coronary anomalies (221/1,751[12.6%] vs 358/4,599 [7.8%], P < .001) and transposition of the great arteries + double outlet right ventricle (109/1,751 [6.2%] vs 313/4,599 [6.8%], P = .01). Aspirin use increased from 17% of case in 2004 to 39% in 2022. The number of centers using aspirin for ≥50% of their ASO patients increased from 2004 to 2008: 4 centers to 2019 to 2022: 15 centers (out of 32 centers with consistent participation) with a greater proportion of high-volume centers using aspirin. Overall, the aspirin group had lower in-hospital mortality (16/1,751 [0.9%] vs 155/4,599 [3.4%], P < .001) and similar rates of reoperation for bleeding (59/1,751 [3.4%] vs 203/4,599 [4.4%], P = .06) and postoperative extracorporeal membrane oxygenation (70/1,755 [4%] vs 195/4,599 [4.2%], P = .67). After adjusting for confounders, the mortality difference remained significant: odds ratio: 0.22 (95%CI: 0.10-0.47), P < .001. Conclusion Considerable variation exists in the use of aspirin post-ASO with an overall increasing trend in aspirin use. In this study, the use of aspirin did not result in an increase in postoperative bleeding or other major adverse events. Prospective studies are needed to confirm the safety and benefits of aspirin.
No takes yet. Share an insight, caveat, or question.
Bedzra et al. (2025) conducted a cohort in Post-arterial switch operation (ASO) (n=6,350). Aspirin vs. No aspirin was evaluated on In-hospital mortality (OR 0.22, 95% CI 0.10-0.47, p=<0.001). Aspirin use following the arterial switch operation was associated with lower in-hospital mortality compared to no aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: